>
Switch to:

Myovant Sciences Financial Strength

: 3 (As of Mar. 2022)
View and export this data going back to 2016. Start your Free Trial

Myovant Sciences has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.

Warning Sign:

Myovant Sciences Ltd displays poor financial strength. Usually this is caused by too much debt for the company.

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3. Altman Z-Score.

Myovant Sciences did not have earnings to cover the interest expense. Myovant Sciences's debt to revenue ratio for the quarter that ended in Mar. 2022 was 1.60. As of today, Myovant Sciences's Altman Z-Score is -2.80.


Competitive Comparison

For the Biotechnology subindustry, Myovant Sciences's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Myovant Sciences Financial Strength Distribution

For the Biotechnology industry and Healthcare sector, Myovant Sciences's Financial Strength distribution charts can be found below:

* The bar in red indicates where Myovant Sciences's Financial Strength falls into.



Myovant Sciences Financial Strength Calculation

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

Myovant Sciences's Interest Expense for the months ended in Mar. 2022 was $-3.5 Mil. Its Operating Income for the months ended in Mar. 2022 was $-51.9 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $365.7 Mil.

Myovant Sciences's Interest Coverage for the quarter that ended in Mar. 2022 is

Myovant Sciences did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

2. Debt to revenue ratio. The lower, the better.

Myovant Sciences's Debt to Revenue Ratio for the quarter that ended in Mar. 2022 is

Debt to Revenue Ratio=Total Debt (Q: Mar. 2022 ) / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(2.148 + 365.741) / 230.268
=1.60

3. Altman Z-Score.

Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

The zones of discrimination were as such:

When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.

Myovant Sciences has a Z-score of -2.80, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

Warning Sign:

Altman Z-score of -2.8 is in distress zone. This implies bankrupcy possibility in the next two years.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Myovant Sciences  (NYSE:MYOV) Financial Strength Explanation

The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.

Myovant Sciences has the Financial Strength Rank of 3. It displays poor financial strength and is likely in financial distress. Usually this is caused by too much debt for the company.


Myovant Sciences Financial Strength Related Terms

Thank you for viewing the detailed overview of Myovant Sciences's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.


Myovant Sciences Business Description

Myovant Sciences logo
Industry
Healthcare » Biotechnology NAICS : 541714 SIC : 2834
Traded in Other Exchanges
Address
11-12 St. James’s Square, Suite 1, 3rd Floor, London, GBR, SW1Y 4LB
Myovant Sciences Ltd is a healthcare company focused on redefining care for women and for men. The company's lead product candidate is relugolix, a once-daily, oral GnRH receptor antagonist. It has three late-stage clinical programs for relugolix in uterine fibroids, endometriosis, and prostate cancer. The company is also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, that has completed a Phase 2a study for the treatment of female infertility as part of assisted reproduction.
Executives
Potter Myrtle S director 10 FINDERNE AVE BRIDGEWATER NJ 08807
Guinan Mark director C/O QUEST DIAGNOSTICS 500 PLAZA DRIVE SECAUCUS NJ 07094
Arjona Ferreira Juan Camilo officer: Chief Medical Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Curran Terrie director C/O MYOVANT SCIENCES INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Gulfo Adele M. director ONE NEENAH CENTER, 4TH FLOOR P.O. BOX 669 NEENAH WI 54957
Sebelius Kathleen director C/O DERMIRA, INC. 275 MIDDLEFIELD ROAD, SUITE 150 MENLO PARK CA 94025
Lang Matthew officer: General Counsel & Corp. Secy. C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY, 9TH FLOOR BRISBANE CA 94005
Sumitomo Chemical Co., Ltd. 10 percent owner 27-1, SHINKAWA 2-CHOME CHUO-KU TOKYO M0 104-8260
Sumitovant Biopharma Ltd. 10 percent owner C/O ROIVANT SCIENCES, INC. 320 WEST 37TH STREET, 5TH FLOOR NEW YORK NY 10018
Dainippon Sumitomo Pharma Co Ltd 10 percent owner 60 WALL STREET NEW YORK NY 10005
Seely Lynn director, officer: Principal Executive Officer 501 2ND STREET SUITE 211 SAN FRANCISCO CA 94107
Sablich Kim officer: Chief Commercial Officer C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Nomura Hiroshi director C/O MYOVANT SCIENCES INC. 2000 SIERRA POINT PARKWAY BRISBANE CA 94005
Roivant Sciences Ltd. 10 percent owner CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Torti Frank director 2855 SAND HILL ROAD MENLO PARK CA 94025

Myovant Sciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)